Core Insights - Cidara Therapeutics, Inc. will present a late-breaking abstract at the European Scientific Working Group on Influenza's 10th Influenza Conference in Valencia, Spain, from October 20-23, 2025 [1][2] Company Overview - Cidara Therapeutics is focused on developing drug-Fc conjugate (DFC) therapeutics using its proprietary Cloudbreak® platform [2] - The lead DFC candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose by inhibiting viral proliferation [2] - CD388 received Fast Track Designation from the FDA in June 2023 and has shown positive top-line results from the Phase 2b NAVIGATE trial completed in June 2025 [2] - The company initiated its Phase 3 ANCHOR trial in September 2025 [2] - Cidara is headquartered in San Diego, California [2]